Rheumnow Podcast

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com RheumNow Live 2025: Register now! RheumNow.live

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com Join us at RheumNow Live February 8 & 9 in Dallas, TX! https://t.co/7WawLxwBLP

This year at ACR24, the RheumNow faculty and reporters were prolific, generating 800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR 2024 by A) Rheumatology Roundup; b) TOPIC Panel podcasts; and c) Topic podcasts. This weeks notable citations on RheumNow.com

Discover the latest advancements in targeting the IL-17 pathway from the ACR Annual Meeting! This expert-led panel will delve into groundbreaking research and therapeutic strategies for managing rheumatic diseases.

Join us for an in-depth discussion about the ACR Annual Meeting! This expert panel will explore the latest research and clinical applications of JAK and TYK inhibitors in managing rheumatic diseases. Stay informed about the cutting-edge therapies shaping the future of rheumatology care. Dr. Janet Pope London, Ontario Dr. David Liew Melbourne Dr. Michael Putman Milwaukee

Panelists: Dr. Jonathan Kay, Dr. Jiha Lee, Dr. Eric Dein and Dr. Jeffrey Sparks

Tune in for an engaging discussion at the ACR Annual Meeting! This expert panel will explore the latest breakthroughs and trends in Psoriatic Arthritis(PsA) research and management, providing actionable insights for clinicians and researchers.

Highlight presentations from ACR 2024 in Washington, DC Covered abstracts include: - Dr. Kavanaugh 1679 Amplified & biomarkers 0082 Enthesitis Pathology & IL-23 1553 TLR 7/8 inhibitors in SLE 995 Carbon footprint to injectables L20 ARTHUR DIANA Automated US 1132 VEGA (Combo Rx – see also 2640, 1460, 1393) 1745 Statin use in Oral Surveillance - Dr. Cush 458 Seronegative RA fate L19 Emapalumab in Stills disease ACR 2024 updated guidelines on lupus nephritis 2580 Ianalumab in SLE 2259 Anti-Obesity Meds in RA 2657 Mortality with starting/stopping steroids 0774 TAPIR study in GCA 1697 PMR MODE study

Join us as we dive into expert insights from the ACR Annual Meeting! This special panel will focus on the latest research and advancements in Spondyloarthritis (SpA), featuring thought leaders in the field. Dr. Marina Magrey Cleveland Dr. Lihi Eder Toronto Dr. Sheila Reyes Phillipines Dr. Adela Castro Memphis

A New ACR Cancer Survival in RA "Changing Mindsets about Methotrexate Side Effects" Control RA, Build Stronger Bones Cumulative Steroid Use and Cardiovascular Events Disease Activity in RA-ILD Do TNFis and JAKis Prevent Cancer!? Estimating Inflammation, Damage and Patient Distress Finding the Right Combination Therapy in RA Implantable Vagus Nerve Stimulator for RA Is Frequent Lab Monitoring Necessary? Long Term Follow up from APIPPRA Metabolic Dysregulation and RA Interstitial Lung Disease Native Americans with RA Die Young Paraoxonase-1: Possible Biomarker for Progression to RA Pred Softly: Steroids Predicting Flares in Rheumatoid Arthritis RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA Treatment Adherence: Is decision making really shared? RA: One JAK to Rule Them All? Sonelokimab in PsA: Phase 2 Data Treat-to-Target Improves Fertility in Women with RA Treatment Considerations for RA-ILD Treatment Strategies in RA Use of AI in Hand Ultrasound Scoring Vaccine Responses:The DMARD Counts What's New in Relapsing Polychondritis? What's The State of Biosimilars?

A New ACR Anti IL-17 on Entheseal Biopsy in PsA axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure Best Things I Saw Today in PsA Cycling vs Switching after TNFi Failure in axSpA Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Sonelokimab in PsA: Phase 2 Data Treating SpA

A New ACR Best Things I Saw Today in PsA Do TNFis and JAKis Prevent Cancer!? Hold or continue JAKi and IL-17 when receiving COVID boosters? JAK-pot! How fast do DMARDs work? JAKi Studies at ACR Poly-treatment of Polymyalgia Rheumatica? RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA: One JAK to Rule Them All? SELECT-GCA: Efficacy and Safety of Upadacitinib "SELECT-GCA: Upadacitinib in Giant Cell Arteritis" SELECTing the right patients: upadacitinib in GCA So really, are JAKs Safe? Summary of JAKi Studies The Case for JAKi in PMR The Real Value of JAKi is Beyond RA When, What and How Long to Treat GCA & PMR Worried about CV Risk and JAKi? What about the Steroids?

A Fibroblast Renaissance A New ACR A useful urinary biomarker for lupus nephritis ANA+ and no Autoimmune Disease? Check the liver CAR-T Therapy and Lupus Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis Evaluating ANA Patterns and Titers with AI Neuropsychiatric Lupus: The Forgotten Symptoms The 2024 ACR Guidelines for Lupus Nephritis Vaccine Responses:The DMARD Counts What is MCTD? The Great Debate

A New ACR Assessing ASAS Criteria: CLASSIC Study Results Assessment and management of axSpA Assessment of axSpA Carotid Doppler Ultrasound Screening in Axial SpA Cycling vs Switching after TNFi Failure in axSpA Defining Difficult to Manage axSpA Difficult to manage AxSpA DISH in SpA Gender Differences in AxSpA Highlights in axSpA Hot Topics in axSpA Long-term Safety Profile of Bimekizumab in axSpA and PsA Machine Learning for Predicting Flares in axSpA Precision Immunotherapy in Axial SpA PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Treating SpA What is a Positive MRI in Spondyloarthritis? axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure

A New ACR Apremilast Benefits and Risks in PsA Best Things I Saw Today in PsA Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Biologic Monotherapy vs Combination with cDMARDs in PsA Do TNFis and JAKis Prevent Cancer!? Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Potential Impact of Weight Loss Drugs in Rheumatic Diseases Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis PsA Potpourri PsA Ultrasound Updates PsA: Impact of Sex Sex Differences in Psoriatic Arthritis The Psoriatic March: PsA before PsO Apremilast in PsA: Results from Mosaic Trial Anti IL-17 on Entheseal Biopsy in PsA

Is Frequent Lab Monitoring Necessary?:Dr. Bella Mehta The Case for JAKi in PMR:Dr. David Liew Treatment Strategies in RA:Dr. Victoria Konzett What's New in Relapsing Polychondritis?:Dr. Bella Mehta Worried about CV Risk and JAKi? What about the Steroids?:Dr. David Liew

ANCA Vasculitis "Eye": Can rituximab help?:Dr. Janet Pope Apremilast in PsA: Results from Mosaic Trial:Dr. Guillermo Valenzuela Implantable Vagus Nerve Stimulator for RA:Dr. Guillermo Valenzuela Treat-to-Target Improves Fertility in Women with RA:Dr. Richard Conway

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care. Join us live and stay at the forefront of rheumatology!

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros Can We Make Clinical Trials Better?:Dr. Janet Pope Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes So really, are JAKs Safe?:Dr. Janet Pope Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey, Louise Pollard and Bharat Kumar The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes The Real Value of JAKi is Beyond RA:Dr. David Liew Vaccine Responses:The DMARD Counts:Dr. David Liew

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care. Join us live and stay at the forefront of rheumatology!